{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:30:57Z","timestamp":1785425457240,"version":"3.56.0"},"reference-count":39,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,8,17]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist therapy) and psychosocial (eg, cognitive behavioural therapy) therapy; however, the best combination of pharmacologic and psychosocial components is not known. Our objective of the planned study is to conduct a comprehensive systematic review to assess the relative benefits of psychosocial interventions as an adjunct to opioid agonist therapy among persons with OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A comprehensive search for randomised controlled trials published in English or French will be conducted from database inception to March 2018. The search will be conducted in MEDLINE and translated for Embase, PsycINFO and the Cochrane Central Register of Controlled Trials. Two independent reviewers will screen, extract and assess risk of bias of eligible articles. Primary outcomes of interest will be treatment retention and opioid use (based on urinalysis results). Secondary outcomes will include self-reported opioid use, abstinence from illicit drugs, adherence to psychosocial therapy and opioid agonist therapy, risk for sexually transmitted disease, risk for blood borne pathogens, changes in mental health symptoms (eg, depression), measures of craving and changes in patients\u2019 quality of life and relevant adverse events. If sufficient data and adequate homogeneity exists, network meta-analyses (NMA) will be performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This will be the first systematic review to incorporate NMA to compare psychosocial treatments used as an adjunct to opioid agonist therapy for OUD. Results of this review will inform clinical management of persons with OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>CRD42018090761.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-023902","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T02:36:09Z","timestamp":1539916569000},"page":"e023902","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-7005","authenticated-orcid":false,"given":"Danielle B","family":"Rice","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Psychology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Poulin","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Faculties of Social Sciences and Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Pain Clinic, Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A","family":"Sproule","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Leslie Dan Faculty of Pharmacy and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moher","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Garber","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Taha","sequence":"additional","affiliation":[{"name":"Canadian Center on Substance Use and Addiction, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Porath","sequence":"additional","affiliation":[{"name":"Canadian Center on Substance Use and Addiction, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Willows","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Substance Use and Concurrent Disorders Program, The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Esmaeilisaraji","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yazdi","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Corace","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Substance Use and Concurrent Disorders Program, The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada"},{"name":"Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"2025121510125903000_8.10.e023902.1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181b01710"},{"key":"2025121510125903000_8.10.e023902.2","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121510125903000_8.10.e023902.3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2025121510125903000_8.10.e023902.4","unstructured":"Canadian Institute for Health Information. Canadian centre on substance abuse. Hospitalizations and emergency department visits due to opioid poisoning in canada: Canadian Institute for Health Information, 2016."},{"key":"2025121510125903000_8.10.e023902.5","unstructured":"Centers for Disease Control Prevention, 2017. Drug overdose death data 2017. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html (accessed 4 Jan 2018)."},{"key":"2025121510125903000_8.10.e023902.6","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2018: trends and developments. Luxembourg: Publications Office of the European Union, 2018. (accessed 5 Jul 2018)."},{"key":"2025121510125903000_8.10.e023902.7","unstructured":"United Nations Office on Drugs and Crime, 2015. World Drug Report 2015. http:\/\/www.unodc.org\/documents\/wdr2015\/World_Drug_Report_2015.pdf"},{"key":"2025121510125903000_8.10.e023902.8","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2017: trends and developments. Luxembourg: Publications Office of the European Union, 2017."},{"key":"2025121510125903000_8.10.e023902.9","unstructured":"British Columbia Centre on Substance Use, British Columbia Ministry of Health, 2017. A guideline for the clinical management of opioid use disorder. http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf (accessed on 15 Jan 2018)."},{"key":"2025121510125903000_8.10.e023902.10","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2011. Guidelines for the treatment of drug dependence: a european perspective. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/651\/SI_treatment-guidelines-p3_315812.pdf (accessed 8 Jul 2018)."},{"key":"2025121510125903000_8.10.e023902.11","unstructured":"Department of Mental Health, Substance Abuse, World Health Organization, International Narcotics Control Board, United Nations Office on Drugs and Crime, 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43948\/9789241547543_eng.pdf;jsessionid=7CBE9320168C572DC76AE3F822237657?sequence=1 (Accessed on 08\/Jul\/2018)."},{"key":"2025121510125903000_8.10.e023902.12","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2025121510125903000_8.10.e023902.13","unstructured":"The Ontario Drug Policy Research Network, 2016. Safety and use of opioids: a summary of ODPRN research on prescription opioid use in Ontario. http:\/\/odprn.ca\/wp-content\/uploads\/2016\/08\/FINAL-ODPRN-Opioids-Summary-Report-Aug-2016_compressed.pdf (accessed 15 Jan 2018)."},{"key":"2025121510125903000_8.10.e023902.14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031914-122957"},{"key":"2025121510125903000_8.10.e023902.15","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2016.06.160073"},{"key":"2025121510125903000_8.10.e023902.16","unstructured":"Canadian Institute for Health Information. Prescribed drug spending in Canada, 2016: a focus on public drug programs: Canadian Institute for Health Information, 2016."},{"key":"2025121510125903000_8.10.e023902.17","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000625"},{"key":"2025121510125903000_8.10.e023902.18","unstructured":"National Collaborating Centre for Mental Health. Drug misuse: psychosocial interventions national clinical practice guideline number 51. London: National Institute for Health and Clinical Excellence, 2008."},{"key":"2025121510125903000_8.10.e023902.19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/2046-4053-3-105","article-title":"The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol","volume":"3","author":"Dennis","year":"2014","journal-title":"Syst Rev"},{"key":"2025121510125903000_8.10.e023902.20","unstructured":"Dennis B . Chronic pain: a red herring or risk factor in the management of patients receiving opioid substitution therapy: McMaster University, 2015. (accessed 4 Jan 2018)."},{"key":"2025121510125903000_8.10.e023902.21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J Addict Med"},{"key":"2025121510125903000_8.10.e023902.22","doi-asserted-by":"crossref","unstructured":"Smedslund G , Berg RC , Hammerstr\u00f8m KT , et al . Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011:CD008063.doi:10.1002\/14651858.CD008063.pub2","DOI":"10.1002\/14651858.CD008063.pub2"},{"key":"2025121510125903000_8.10.e023902.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10826084.2017.1325376","article-title":"Primary care physicians' views about prescribing methadone to treat opioid use disorder","volume":"53","author":"Livingston","year":"2018","journal-title":"Subst Use Misuse"},{"key":"2025121510125903000_8.10.e023902.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2994-2"},{"key":"2025121510125903000_8.10.e023902.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"2025121510125903000_8.10.e023902.26","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"2025121510125903000_8.10.e023902.27","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2025121510125903000_8.10.e023902.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.10.012"},{"key":"2025121510125903000_8.10.e023902.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03490.x"},{"key":"2025121510125903000_8.10.e023902.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.07.018"},{"key":"2025121510125903000_8.10.e023902.31","doi-asserted-by":"publisher","DOI":"10.1037\/a0016597"},{"key":"2025121510125903000_8.10.e023902.32","doi-asserted-by":"crossref","unstructured":"Moher D , Liberati A , Tetzlaff J , et al . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2008;6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025121510125903000_8.10.e023902.33","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121510125903000_8.10.e023902.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025121510125903000_8.10.e023902.35","unstructured":"Dias S , Sutton A , Welton N , et al , 2012. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. http:\/\/www.nicedsu.org.uk\/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed on 2 Feb 2018)."},{"key":"2025121510125903000_8.10.e023902.36","unstructured":"Dias S , Welton N , Sutton A , et al , 2011. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. http:\/\/wwwnicedsuorguk"},{"key":"2025121510125903000_8.10.e023902.37","unstructured":"American Society of Addiction Medicine, 2013. Advancing access to addiction medicine: implications for opioid addiction treatment. https:\/\/www.asam.org\/docs\/default-source\/advocacy\/aaam_implications-for-opioid-addiction-treatment_final (accessed 2 Feb 2018)."},{"key":"2025121510125903000_8.10.e023902.38","unstructured":"Ministry of Health Long Term Care, 2016. Methadone treatment and services advisory committee: final report. http:\/\/health.gov.on.ca\/en\/public\/programs\/drugs\/ons\/docs\/methadone_advisory_committee_report.pdf (accessed 2 Feb 2018)."},{"key":"2025121510125903000_8.10.e023902.39","unstructured":"Centre for Addiction and Mental Health, 2016. Prescription opioid policy framework. https:\/\/www.camh.ca\/en\/hospital\/about_camh\/influencing_public_policy\/Documents\/CAMHopioidpolicyframework.pdf (accessed 7 Feb 2018)."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-023902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:13:11Z","timestamp":1765822391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-023902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,18]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/bmjopen-2018-023902"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-023902","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}